CN Patent

CN114829375A — 具有降低的副作用的hdac治疗的剂量

Assigned to Villakta Subsidiary · Expires 2022-07-29 · 4y expired

What this patent protects

本文描述了有效预防和管理与组蛋白脱乙酰基酶抑制剂(HDACi)治疗相关的副作用的某些给药方案和给药量。任选地，这些方案以及给药方案包括用抗病毒剂治疗。

USPTO Abstract

本文描述了有效预防和管理与组蛋白脱乙酰基酶抑制剂(HDACi)治疗相关的副作用的某些给药方案和给药量。任选地，这些方案以及给药方案包括用抗病毒剂治疗。

Drugs covered by this patent

Patent Metadata

Patent number
CN114829375A
Jurisdiction
CN
Classification
—
Expires
2022-07-29
Drug substance claim
No
Drug product claim
No
Assignee
Villakta Subsidiary
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.